143 related articles for article (PubMed ID: 2314008)
21. [Hemodynamic effects of intermittent intra-arterial infusion treatment with prostaglandin E1 in peripheral arterial occlusive disease].
Ranke C; Creutzig A; Alexander K
Med Klin (Munich); 1991 Jul; 86(7):349-52, 382. PubMed ID: 1921896
[TBL] [Abstract][Full Text] [Related]
22. Hemodynamic effects of intravenous PGE1 on patients with arterial occlusive disease of the leg.
Hirai M; Nanki M; Nakayama R
Angiology; 1985 Jul; 36(7):407-13. PubMed ID: 4040721
[TBL] [Abstract][Full Text] [Related]
23. Transcutaneous PO2 and laser Doppler flowmetry in patients with arterial occlusive disease receiving intraarterial infusions of PGE1 or nucleotide phosphates.
Caspary L; Creutzig A; Alexander K
Prog Clin Biol Res; 1987; 242():433-8. PubMed ID: 2959965
[No Abstract] [Full Text] [Related]
24. Influence of prostaglandin E1 on muscular tissue-PO2 in patients with diabetic gangrene.
Heinrich R; Krawzak HW; Strosche H
Adv Exp Med Biol; 1989; 248():699-704. PubMed ID: 2506745
[TBL] [Abstract][Full Text] [Related]
25. Drug-induced alterations in muscle tissue oxygen pressure in patients with arterial occlusive disease.
Creutzig A; Alexander K
Int J Microcirc Clin Exp; 1985; 4(2):173-81. PubMed ID: 2412983
[TBL] [Abstract][Full Text] [Related]
26. Effect of intermittent venous occlusion on transcutaneous oxygen tension in lower limbs with severe arterial occlusive disease.
Rooke TW; Osmundson PJ
Int J Cardiol; 1988 Oct; 21(1):76-8. PubMed ID: 3220605
[TBL] [Abstract][Full Text] [Related]
27. [Duplex ultrasound measurement of hemodynamic parameters at rest and following arterial stenosis: effect of intra-arterial infusion therapy with prostaglandin E1].
Ranke C; Creutzig A; Alexander K
Vasa Suppl; 1989; 27():353-5. PubMed ID: 2696104
[No Abstract] [Full Text] [Related]
28. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
Hesse WH; Rudofsky G; Peskar BA
Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
[TBL] [Abstract][Full Text] [Related]
29. Influence of percutaneous transluminal angioplasty on transcutaneous oxygen pressure in patients with peripheral arterial occlusive disease.
Wagner HJ; Schmitz R; Alfke H; Klose KJ
Radiology; 2003 Mar; 226(3):791-7. PubMed ID: 12601207
[TBL] [Abstract][Full Text] [Related]
30. PGE(1) short term therapy in critical lower limb ischemia.
Bandiera G; Forletta M; Di Paola FM; Cirielli C
Int Angiol; 2003 Mar; 22(1):58-63. PubMed ID: 12771858
[TBL] [Abstract][Full Text] [Related]
31. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
[TBL] [Abstract][Full Text] [Related]
32. Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease.
Peskar BA; Hesse WH; Rogatti W; Diehm C; Rudofsky G; Schweer H; Seyberth HW
Prostaglandins; 1991 Mar; 41(3):225-8. PubMed ID: 1852896
[TBL] [Abstract][Full Text] [Related]
33. Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia.
Schellong S; Altmann E; von Bilderling P; Rudofsky G; Waldhausen P; Rogatti W
Prostaglandins Leukot Essent Fatty Acids; 2004 Jun; 70(6):503-9. PubMed ID: 15120713
[TBL] [Abstract][Full Text] [Related]
34. [Intravenous administration of PGE1: studies of the effectiveness and duration of the effect of various dosages based on flow measurements of the femoral artery in patients with healthy vessels and in stage IIb arterial occlusive disease].
Scheffler P; Birkel L; Grub KR; de la Hamette D
Vasa Suppl; 1988; 23():126-9. PubMed ID: 3061035
[No Abstract] [Full Text] [Related]
35. [Prostaglandin E1 in intermittent claudication].
Scheffler P; de la Hamette D; Rogatti W
Vasa Suppl; 1992; 35():147-8. PubMed ID: 1481022
[No Abstract] [Full Text] [Related]
36. Neutrophil function in peripheral arterial occlusive disease: the effects of prostaglandin E1.
Weiss T; Eckstein H; Weiss C; Diehm C
Vasc Med; 1998; 3(3):171-5. PubMed ID: 9892509
[TBL] [Abstract][Full Text] [Related]
37. [The skin oxygen histogram in patients with arterial occlusive disorders].
Creutzig A; Caspary L; Alexander K
Vasa Suppl; 1989; 27():225-7. PubMed ID: 2623500
[No Abstract] [Full Text] [Related]
38. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
Fitscha P; Simmet T; Peskar BA; Reuter H; Sinzinger H; Rogatti W; Tilsner V
Wien Klin Wochenschr; 1988 Jul; 100(14):477-81. PubMed ID: 3062905
[TBL] [Abstract][Full Text] [Related]
39. Treatment of complications of peripheral obstructive arterial disease with prostaglandin E1.
Killion DD; Ambrus JL
Angiology; 1987 Jul; 38(7):507-13. PubMed ID: 3619123
[TBL] [Abstract][Full Text] [Related]
40. [Fully implantable catheter systems for arterial extremity infusion].
Krawzak HW; Strosche H
Chirurg; 1989 Jul; 60(7):475-8. PubMed ID: 2791734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
